Insights

Strategic partnership MimiVax has recently partnered with Roswell Park Comprehensive Cancer Center, and news suggests a spin-off plan. This indicates a potential interest in co-developed programs, joint ventures, or license-out opportunities that leverage established oncology networks and clinical trial capabilities.

Clinical-stage momentum Lead product SurVaxM has progressed to Phase 2a for newly diagnosed glioblastoma, with ongoing Phase 1 trials in multiple myeloma combinations and neuro-endocrine tumors. This signals a pipeline with near-term collaboration potential around trial support, biomarker work, or access to trial sites.

Global reach Past collaborations include Fosun Pharma for U.S. and China territories, indicating an openness to international partnerships and distribution. This presents growth opportunities in Asia-Pacific and other regions through licensing, co-development, or regional manufacturing deals.

Small but agile With a lean team and recent growth through spin-off history, MimiVax is likely seeking scalable partnerships that provide access to broader commercialization expertise, manufacturing capacity, and capital-efficient collaboration models for clinical-stage assets.

Immunotherapy focus Specializing in immunotherapeutic vaccines and targeted therapies for cancer, MimiVax offers a niche oncoprimary program alignment. Sales opportunities exist with CROs, diagnostic partners, and biopharma players seeking to augment immuno-oncology portfolios or pursue combination strategies.

Similar companies to MimiVax, Inc.

MimiVax, Inc. Tech Stack

MimiVax, Inc. uses 8 technology products and services including Hotjar, Cloudflare, Open Graph, and more. Explore MimiVax, Inc.'s tech stack below.

  • Analytics
  • Cloudflare
    Content Management System
  • Open Graph
    Content Management System
  • Content Management System
  • E-commerce
  • Lightbox
    Javascript Libraries
  • Really Simple Discovery
    Miscellaneous
  • HTTP/3
    Web & Portal Technology

Media & News

MimiVax, Inc.'s Email Address Formats

MimiVax, Inc. uses at least 2 email formats:
MimiVax, Inc. Email FormatsExamplePercentage
FLast@mimivax.comJDoe@mimivax.com
75%
First.Last@mimivax.comJohn.Doe@mimivax.com
25%

Frequently Asked Questions

What is MimiVax, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact MimiVax, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is MimiVax, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
MimiVax, Inc.'s official website is mimivax.com and has social profiles on LinkedIn.

How much revenue does MimiVax, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, MimiVax, Inc.'s annual revenue is estimated to be $1M - $10M.

What is MimiVax, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
MimiVax, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does MimiVax, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, MimiVax, Inc. has approximately 4 employees across 1 continents, including North America. Key team members include Vice President Business Development And Strategy: A. C. and President & Ceo: M. C. Explore MimiVax, Inc.'s employee directory with LeadIQ.

What industry does MimiVax, Inc. belong to?

Minus sign iconPlus sign icon
MimiVax, Inc. operates in the Biotechnology Research industry.

What technology does MimiVax, Inc. use?

Minus sign iconPlus sign icon
MimiVax, Inc.'s tech stack includes Hotjar, Cloudflare, Open Graph, WordPress, Shopify, Lightbox, Really Simple Discovery and HTTP/3.

What is MimiVax, Inc.'s email format?

Minus sign iconPlus sign icon
MimiVax, Inc.'s email format typically follows the pattern of FLast@mimivax.com. Find more MimiVax, Inc. email formats with LeadIQ.

How much funding has MimiVax, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, MimiVax, Inc. has raised $17M in funding. The last funding round occurred on Jan 09, 2024.

When was MimiVax, Inc. founded?

Minus sign iconPlus sign icon
MimiVax, Inc. was founded in 2012.
MimiVax, Inc. logo

MimiVax, Inc.

Biotechnology ResearchNew York, United States2-10 Employees

MimiVax, Inc. is a privately held biotechnology company based in Buffalo, New York, focused on developing and commercializing immunotherapeutic vaccines and targeted cancer therapies. Its lead candidate, SurVaxM, has completed a Phase 2a trial in adults with newly diagnosed glioblastoma. Recent reporting indicates the company originated as a spin-off from Roswell Park Comprehensive Cancer Center.

The company is evaluating additional indications through early-phase trials in multiple myeloma in combination with lenalidomide, Neuro-Endocrine Tumors, and pediatric high-grade glioma. In October 2023, the FDA granted SurVaxM Fast Track Designation for the management of newly diagnosed glioblastoma.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2012
Employees
2-10

Section iconFunding & Financials

  • $17M

    MimiVax, Inc. has raised a total of $17M of funding over 4 rounds. Their latest funding round was raised on Jan 09, 2024 as a Venture Round.

  • $1M - $10M

    MimiVax, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.